AHEAD OF THE CURVE: CF SUMMIT

New Users: Register Below

Click the button below to register for the presentation.

Register

Returning Users: Log In

Login

MICHAEL P. BOYLE, MD, FCCP

Associate Professor of Medicine
Director, Johns Hopkins Adult Cystic Fibrosis Program
Baltimore, Maryland

PETER J. MOGAYZEL, Jr, MD, PhD

Associate Professor of Pediatrics
Director, Cystic Fibrosis Center
Johns Hopkins Cystic Fibrosis Center
Baltimore, Maryland

MEGHAN RAMSAY, MS, FRCP

Clinical Coordinator
Johns Hopkins Adult Cystic Fibrosis Program
Baltimore, Maryland


	J. STUART ELBORN, MD, FRCP Professor of Respiratory Medicine Centre for Infection and Immunity Queen’s University of Belfast Belfast, Northern Ireland United Kingdom EITAN KEREM, MD Head, Department of Pediatrics Cystic Fibrosis Center Hadassah Medical Center Mount Scopus, Jerusalem

WEBCAST #1

PROGRAM GOALS
Recent Treatment Guidelines and Practices:

Overview of recently published care guidelines
International perspective of guideline base care
Optimal use of specific therapies (eg hydration, mucolytic and anti-inflammatory therapies)
The risks/benefits of polypharmacy
Developing an individual care plan for patients

Emerging Disease-Modifying CF Therapies:

Novel therapies on the horizon (Mannitol and Denufosol)
Disease modifying therapies that affect CFTR
Managing expectations for novel therapies

WEBCAST #2

PROGRAM GOALS
Treating Mild Lung Disease:

How does the advent of pre-symptomatic diagnosis of children alter approach to therapy
Prophylactic use of therapies vs. symptomatic care

Adherence Improvement Models:

Current data on adherence to CF therapies
Present currently successful CF adherence improvement models
How approval of CFTR modulating therapies will impact adherence

STATEMENT OF NEED

Incorporating screening protocols, new data on symptomatic treatment modalities and up-to-the-minute research findings, this program will address the core patient care gaps:

Clinicians do not have adequate knowledge to effectively discuss emerging treatments for the symptoms of CF.
CF clinicians require increased knowledge to more effectively answer their patients' questions about emerging therapies targeted to the prevention/remission of primary disease.
CF clinicians are unprepared to make optimal use of screening data (newborn and other).
CF clinicians are not aware of emerging best practices in improving patient adherence to therapeutic interventions.

INTENDED AUDIENCE

Clinicians involved in treating and managing patients with cystic fibrosis, including pulmonologists, pediatric pulmonologists, pediatricians, gastroenterologists, infectious disease specialists, physician assistants, nurse practitioners and nurses. There are no prerequisites.

ACCREDITATION STATEMENT

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the Johns Hopkins University School of Medicine and the Institute for Johns Hopkins Nursing. The Johns Hopkins University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The Institute for Johns Hopkins Nursing is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. The Institute for Johns Hopkins Nursing and the American Nurses Credentialing Center do not endorse the use of any commercial products discussed or displayed in conjunction with this educational activity.

CREDIT DESIGNATION

PHYSICIANS: (Each Prerecorded Webcast) The Johns Hopkins University School of Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s)^™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

NURSES: 2.0 contact hour Educational Activity is provided by the Institute for Johns Hopkins Nursing. Each webcast carries a maximum of 1.0 contact hour Education Activity provided by the Institute for Johns Hopkins Nursing; or a total of 2.0 contact hours for the two webcasts in this program.

To obtain contact hours, you must complete this Education Activity and post-test before March 2, 2013.
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit^™ from organizations accredited by the ACCME. Physician assistants may receive a maximum of 2 hours of Category 1 credit for completing this program.

Respiratory Therapists
For United States:
Click here to confirm that your state will accept the CE credits gained through this program.
For Canada:
Click here to confirm that your province will accept the CE credits gained through this program.

LEARNING OBJECTIVES

After completing this activity, the participant will demonstrate the ability to:

Identify the potential benefits/risks of therapeutic targets used alone and in combination to alleviate CF symptoms.
Summarize the known data regarding ongoing research into CFTR modulators
Appraise the impact approved CFTR modulators may have on current practice paradigms.
Evaluate how increased screening can improve patient outcomes with current therapies and how those who are newly screened may be affected by the approval of CFTR modulators.
Formulate optimal strategies for improving adherence to current CF therapies and evaluate how these strategies may be impacted by the approval of CFTR modulators.
Explain the current research on salt transport/correcting ion transport, P2Y2 agonists, ENaC antagonists, et al.
Integrate this information into current clinical practice to more effectively advise and counsel patients, manage patient expectations, and improve patient quality of life.

STATEMENT OF RESPONSIBILITY

The Johns Hopkins University School of Medicine takes responsibility for the content, quality, and scientific integrity of this CME activity.

Enduring Materials
Release date
April 15, 2011
Expiration Date
April 14, 2013

PRIVACY STATEMENT

The Office of Continuing Medical Education (CME) at the Johns Hopkins University School of Medicine is committed to protecting the privacy of its members and customers. Johns Hopkins University SOM CME maintains its Internet site as an information resource and service for physicians, other health professionals and the public. Continuing Medical Education at the Johns Hopkins University School of Medicine will keep your personal and credit information confidential when you participate in a CME Internet based program privacy statement. Your information will never be given to anyone outside of the Johns Hopkins University School of Medicine's CME program. CME collects only the information necessary to provide you with the services that you request.

FACULTY DISCLOSURE

As a provider approved by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of the Johns Hopkins University School of Medicine Office of Continuing Medical Education (OCME) to require signed disclosure of the existence of financial relationships with industry from any individual in a position to control the content of a CME activity sponsored by OCME. Members of the Planning Committee are required to disclose all relationships regardless of their relevance to the content of the activity. Faculty are required to disclose only those relationships that are relevant to their specific presentation. The following relationships have been reported for this activity:

Name	Lecture titles	Company
Michael P. Boyle, MD, FCCP Planner/Faculty Disclosure	Recent Treatment Guidelines: for the Adult CF patient Emerging Disease-Modifying CF Therapies Treatment Approaches for the Asymptomatic/Mild adult patient Adherence Improvement Models	Grants/Research Support: Vertex Pharmaceuticals, Inc. Consultant: Bayer, Pharmaxis, Vertex Pharmaceuticals, Inc.
Peter J. Mogayzel, Jr., MD, PhD Planner/Faculty Disclosure	Recent Treatment Guidelines: for the pediatric CF patient Review of CF Pathophysiology Treatment Approaches for the Asymptomatic/Mild pediatric patient	Discloses that he has no financial relationship with commercial supporters.
Meghan Ramsay, MS, CRNP Planner/Faculty Disclosure	Recent Treatment Guidelines: a nursing perspective Treatment Approaches for the Asymptomatic/Mild CF Child and Adult: a nursing perspective	Discloses that she has no financial relationship with commercial supporters.
J. Stuart Elborn, MD, FRCP Guest Faculty	Recent Treatment Guidelines: an International Perspective Emerging Disease Modifying CF Therapies	Grants/Research Support: Vertex Pharmaceuticals, Inc. Consultant: Bayer, Gilead, MPex Honorarium: Forest
Eitan Kerem, MD Guest Faculty	Treatment Approaches for the Asymptomatic/Mild CF Child and Adult Adherence Improvement Models	Discloses that he has no financial relationship with commercial supporters.

Grants to investigators at The Johns Hopkins University are negotiated and administered by the institution which receives the grants, typically through the Office of Research Administration. Individual investigators who participate in the sponsored project(s) are not directly compensated by the sponsor, but may receive salary or other support from the institution to support their effort on the project(s).

ACKNOWLEDGEMENT OF COMMERCIAL SUPPORT

Supported by an educational grant from Vertex Pharmaceuticals, Inc.

OFF-LABEL PRODUCT DISCUSSION

The following speakers have disclosed that their presentation will reference unlabeled/unapproved uses of drugs or products:

Name	Lecture titles	Product
Michael P. Boyle, MD, FCCP Program Director	Emerging Disease-Modifying CF Therapies	Ataluren/PTC-124, VX-770, VX-809
Peter J. Mogayzel, Jr., MD, PhD Program Director	Recent Treatment Guidelines: for the Pediatric CF patient Emerging Disease Modifying CF Therapies Pediatric Issues in the Treatment of Mild Lung Disease, Early Intervention Studies For Treatment of Pseudomonas (EPIC AND ELITE)	Tobramycin Denufosol, Mannitol Tobramycin
J. Stuart Elborn, MD, FRCP Guest faculty	Recent Treatment Guidelines: an International Perspective An International Perspective On Emerging Emerging Disease-Modifying CF Therapies	Tobramycin Denefusol, Mannitol
Eitan Kerem, MD Guest faculty	Treatment Approaches for the Asymptomatic/Mild CF Child and Adult	Ataluren/PTC-124 and VX-770

All other speakers have indicated that they will not reference unlabeled/unapproved uses of drugs or products.

DISCLAIMER

The opinions and recommendations expressed by the faculty and other experts whose input is included in this program are their own. This material is produced for educational purposes only. Use of Johns Hopkins University School of Medicine name implies review of educational format design and approach. Please review the complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients.

POST-TEST AND EVALUATION:

A post-test and evaluation is included in the activity. Physicians must document amount of time they spent in the activity. Upon completion of both, participants receiving a grade of 70% or above will receive a CME certificate.

HARDWARE & SOFTWARE REQUIREMENTS

Pentium 800 processor or greater, Windows 98/NT/200/XP or Mac OS 9/X, Microsoft Internet Explorer 5.5 or later, Windows Media Player 9.0 or later, 128 MB of RAM Monitor settings: High color at 800 x 600 pixels, Sound card and speakers, Adobe Acrobat Reader.

Warning: You do not have Flash player installed